A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.

Inclusion Criteria: * Adult patients, \>=18 years of age * Metastatic colorectal cancer and disease progression * Previously treated with first-line chemotherapy plus Avastin * Eastern Cooperative Oncology Group (ECOG) performance status \<=2. Exclusion Criteria: * Diagnosis of progression of disease more than 3 months after last Avastin administration * First-line patients with progression-free survival in first-line of \<3 months * Patients receiving less than 3 consecutive months of Avastin in first-line therapy * Past or current history (within the last 2 years prior to treatment start) of other malignancies, except for curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix * Clinically significant cardiovascular disease within 6 months prior to start of study treatment * Known central nervous system (CNS) disease, except for treated CNS metastases as defined by protocol